Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.
2.

Resistance decay in individuals after antibiotic exposure in primary care: a systematic review and meta-analysis.

Bakhit M, Hoffmann T, Scott AM, Beller E, Rathbone J, Del Mar C.

BMC Med. 2018 Aug 7;16(1):126. doi: 10.1186/s12916-018-1109-4. Review.

3.

Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.

Soares-Weiser K, Rathbone J, Ogawa Y, Shinohara K, Bergman H.

Cochrane Database Syst Rev. 2018 Mar 19;3:CD000208. doi: 10.1002/14651858.CD000208.pub2. Review.

4.

Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Bergman H, Rathbone J, Agarwal V, Soares-Weiser K.

Cochrane Database Syst Rev. 2018 Feb 6;2:CD000459. doi: 10.1002/14651858.CD000459.pub3. Review.

5.

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.

El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H.

Cochrane Database Syst Rev. 2018 Jan 18;1:CD000458. doi: 10.1002/14651858.CD000458.pub3. Review.

6.

Expediting citation screening using PICo-based title-only screening for identifying studies in scoping searches and rapid reviews.

Rathbone J, Albarqouni L, Bakhit M, Beller E, Byambasuren O, Hoffmann T, Scott AM, Glasziou P.

Syst Rev. 2017 Nov 25;6(1):233. doi: 10.1186/s13643-017-0629-x. Review.

7.

Systematic review of the effects of care provided with and without diagnostic clinical prediction rules.

Sanders SL, Rathbone J, Bell KJL, Glasziou PP, Doust JA.

Diagn Progn Res. 2017 Apr 26;1:13. doi: 10.1186/s41512-017-0013-2. eCollection 2017. Review.

8.

Droperidol for psychosis-induced aggression or agitation.

Khokhar MA, Rathbone J.

Cochrane Database Syst Rev. 2016 Dec 15;12:CD002830. doi: 10.1002/14651858.CD002830.pub3. Review.

9.

Review article: Role of magnesium sulphate in the management of Irukandji syndrome: A systematic review.

Rathbone J, Franklin R, Gibbs C, Williams D.

Emerg Med Australas. 2017 Feb;29(1):9-17. doi: 10.1111/1742-6723.12694. Epub 2016 Oct 17. Review.

PMID:
27748058
10.

A systematic review of the public's knowledge and beliefs about antibiotic resistance-authors' response.

McCullough AR, Parekh S, Rathbone J, Del Mar CB, Hoffmann TC.

J Antimicrob Chemother. 2016 Aug;71(8):2366. doi: 10.1093/jac/dkw163. Epub 2016 May 10. No abstract available.

PMID:
27169439
11.
12.

A systematic review of the public's knowledge and beliefs about antibiotic resistance.

McCullough AR, Parekh S, Rathbone J, Del Mar CB, Hoffmann TC.

J Antimicrob Chemother. 2016 Jan;71(1):27-33. doi: 10.1093/jac/dkv310. Epub 2015 Oct 12. Review.

PMID:
26459555
13.

Not in my backyard: a systematic review of clinicians' knowledge and beliefs about antibiotic resistance.

McCullough AR, Rathbone J, Parekh S, Hoffmann TC, Del Mar CB.

J Antimicrob Chemother. 2015 Sep;70(9):2465-73. doi: 10.1093/jac/dkv164. Epub 2015 Jun 20. Review.

PMID:
26093375
14.

Faster title and abstract screening? Evaluating Abstrackr, a semi-automated online screening program for systematic reviewers.

Rathbone J, Hoffmann T, Glasziou P.

Syst Rev. 2015 Jun 15;4:80. doi: 10.1186/s13643-015-0067-6.

15.

Fluphenazine decanoate (depot) and enanthate for schizophrenia.

Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE.

Cochrane Database Syst Rev. 2015 Feb 5;(2):CD000307. doi: 10.1002/14651858.CD000307.pub2. Review.

PMID:
25654768
16.

Better duplicate detection for systematic reviewers: evaluation of Systematic Review Assistant-Deduplication Module.

Rathbone J, Carter M, Hoffmann T, Glasziou P.

Syst Rev. 2015 Jan 14;4:6. doi: 10.1186/2046-4053-4-6. Review.

17.

Cannabis and schizophrenia.

Pushpa-Rajah JA, McLoughlin BC, Gillies D, Rathbone J, Variend H, Kalakouti E, Kyprianou K.

Schizophr Bull. 2015 Mar;41(2):336-7. doi: 10.1093/schbul/sbu168. Epub 2014 Dec 30. Review.

18.

Cannabis and schizophrenia.

McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, Kyprianou K.

Cochrane Database Syst Rev. 2014 Oct 14;(10):CD004837. doi: 10.1002/14651858.CD004837.pub3. Review.

PMID:
25314586
19.

The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review.

Poku E, Rathbone J, Wong R, Everson-Hock E, Essat M, Pandor A, Wailoo A.

BMJ Open. 2014 Jul 17;4(7):e005244. doi: 10.1136/bmjopen-2014-005244. Review.

20.

Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation.

Holmes M, Rathbone J, Littlewood C, Rawdin A, Stevenson M, Stevens J, Archer R, Evans P, Wang J.

Health Technol Assess. 2014 Mar;18(16):1-176. doi: 10.3310/hta18160. Review.

21.

Chlorpromazine versus placebo for schizophrenia.

Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K.

Cochrane Database Syst Rev. 2014 Jan 6;(1):CD000284. doi: 10.1002/14651858.CD000284.pub3. Review.

PMID:
24395698
22.

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS).

Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A.

BMJ Open. 2013 Nov 4;3(11):e003573. doi: 10.1136/bmjopen-2013-003573.

23.

Benzodiazepines for psychosis-induced aggression or agitation.

Gillies D, Sampson S, Beck A, Rathbone J.

Cochrane Database Syst Rev. 2013 Sep 18;9:CD003079. [Epub ahead of print]

PMID:
24049046
24.

Haloperidol dose for the acute phase of schizophrenia.

Donnelly L, Rathbone J, Adams CE.

Cochrane Database Syst Rev. 2013 Aug 28;(8):CD001951. doi: 10.1002/14651858.CD001951.pub2. Review.

PMID:
23983042
25.

Benzodiazepines for psychosis-induced aggression or agitation.

Gillies D, Sampson S, Beck A, Rathbone J.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD003079. doi: 10.1002/14651858.CD003079.pub3. Review.

PMID:
23633309
26.

Response to 'Randomised trial of magnesium in the treatment of Irukandji syndrome'.

Rathbone J, Quinn J, Rashford S.

Emerg Med Australas. 2013 Feb;25(1):97-8. doi: 10.1111/1742-6723.12026. No abstract available.

PMID:
23379465
27.

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J.

Health Technol Assess. 2012;16(37):1-253, iii-iv. Review.

28.

Day hospital versus admission for acute psychiatric disorders.

Marshall M, Crowther R, Sledge WH, Rathbone J, Soares-Weiser K.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD004026. doi: 10.1002/14651858.CD004026.pub2. Review.

29.

Early intervention for psychosis.

Marshall M, Rathbone J.

Schizophr Bull. 2011 Nov;37(6):1111-4. doi: 10.1093/schbul/sbr110. Epub 2011 Sep 10. Review. No abstract available.

30.

Early intervention for psychosis.

Marshall M, Rathbone J.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD004718. doi: 10.1002/14651858.CD004718.pub3. Review.

31.

Interventions to improve teamwork and communications among healthcare staff.

McCulloch P, Rathbone J, Catchpole K.

Br J Surg. 2011 Apr;98(4):469-79. doi: 10.1002/bjs.7434. Epub 2011 Feb 8. Review.

PMID:
21305537
32.

Family intervention for schizophrenia.

Pharoah F, Mari J, Rathbone J, Wong W.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD000088. doi: 10.1002/14651858.CD000088.pub2. Review.

33.

Is progesterone a candidate neuroprotective factor for treatment following ischemic stroke?

Gibson CL, Coomber B, Rathbone J.

Neuroscientist. 2009 Aug;15(4):324-32. doi: 10.1177/1073858409333069. Epub 2009 Apr 9. Review.

PMID:
19359672
34.

Clozapine versus typical neuroleptic medication for schizophrenia.

Essali A, Al-Haj Haasan N, Li C, Rathbone J.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD000059. doi: 10.1002/14651858.CD000059.pub2. Review.

PMID:
19160174
35.

Cannabis and schizophrenia.

Rathbone J, Variend H, Mehta H.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004837. doi: 10.1002/14651858.CD004837.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;10:CD004837.

36.

Open general medical wards versus specialist psychiatric units for acute psychoses.

Hickling FW, Abel W, Garner P, Rathbone J.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003290. Review.

37.

Pimozide for schizophrenia or related psychoses.

Rathbone J, McMonagle T.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001949. Review. Update in: Cochrane Database Syst Rev. 2013;11:CD001949.

PMID:
17636692
38.

Thioridazine for schizophrenia.

Fenton M, Rathbone J, Reilly J, Sultana A.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001944. Review.

39.

Schizophrenia trials in China: a survey.

Chakrabarti A, Adams CE, Rathbone J, Wright J, Xia J, Wong W, Von Reibnitz P, Koenig C, Baier S, Pfeiffer C, Blatter J, Mantz M, Kloeckner K.

Acta Psychiatr Scand. 2007 Jul;116(1):6-9. Review.

40.

Chinese herbal medicine for schizophrenia: cochrane systematic review of randomised trials.

Rathbone J, Zhang L, Zhang M, Xia J, Liu X, Yang Y, Adams CE.

Br J Psychiatry. 2007 May;190:379-84. Review.

PMID:
17470951
41.

Chlorpromazine versus placebo for schizophrenia.

Adams CE, Awad G, Rathbone J, Thornley B.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD000284. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD000284.

PMID:
17443500
42.

Early intervention for psychosis.

Marshall M, Rathbone J.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004718. Review. Update in: Cochrane Database Syst Rev. 2011;(6):CD004718.

PMID:
17054213
43.

Anticholinergics for neuroleptic-induced acute akathisia.

Rathbone J, Soares-Weiser K.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003727. Review.

PMID:
17054182
44.

Zotepine for schizophrenia.

DeSilva P, Fenton M, Rathbone J.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001948. Review.

PMID:
17054149
45.

Family intervention for schizophrenia.

Pharoah F, Mari J, Rathbone J, Wong W.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD000088. Review. Update in: Cochrane Database Syst Rev. 2010;(12):CD000088.

PMID:
17054127
46.

Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.

Soares-Weiser K, Rathbone J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD000459. Review. Update in: Cochrane Database Syst Rev. 2018 Feb 06;2:CD000459.

PMID:
16437425
47.

Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia.

El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD000458. Review. Update in: Cochrane Database Syst Rev. 2018 Jan 18;1:CD000458.

PMID:
16437424
48.

Acupuncture for schizophrenia.

Rathbone J, Xia J.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD005475. Review. Update in: Cochrane Database Syst Rev. 2014;10:CD005475.

PMID:
16235404
49.

Chinese herbal medicine for schizophrenia.

Rathbone J, Zhang L, Zhang M, Xia J, Liu X, Yang Y.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003444. Review.

PMID:
16235320
50.

Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis.

Gillies D, Beck A, McCloud A, Rathbone J, Gillies D.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003079. Review. Update in: Cochrane Database Syst Rev. 2013;4:CD003079.

PMID:
16235313

Supplemental Content

Loading ...
Support Center